J&J tops estimates as prescription, OTC drugs shine<p><a href="http://news.yahoo.com/johnson-johnson-results-beat-wall-street-estimates-115658081--finance.html"><img src="http://l.yimg.com/bt/api/res/1.2/UUuYVtx5cVdSoLdl5dhmqQ--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2013-04-16T115658Z_1_CBRE93F0X7L00_RTROPTP_2_JOHNSONANDJOHNSON.JPG" width="130" height="86" alt="Products made by Johnson & Johnson for sale on a store shelf in Westminster" align="left" title="Products made by Johnson & Johnson for sale on a store shelf in Westminster" border="0" /></a>By Ransdell Pierson (Reuters) - Johnson & Johnson beat Wall Street's quarterly profit estimates on sharply lower taxes, strong sales of prescription drugs and a revival of over-the-counter medicines that had been recalled over quality control problems. Newer prescription medicines, including prostate cancer drug Zytiga, psoriasis drug Stelara, and Incivo for hepatitis C made big contributions. J&J shares rose 1.7 percent to $83.13 in mid-day trading. ...</p><br clear="all"/>
Source: J&J tops estimates as prescription, OTC drugs shine (http://news.yahoo.com/johnson-johnson-results-beat-wall-street-estimates-115658081--finance.html)